Tune Therapeutics

Duke researchers found company to mine the new frontier of epigenomics and unlock complex disease.



OTC breaks its record again for revenue in a single fiscal year.

Duke Capital Partners joins OTC

Duke Capital Partners has moved to be a part of OTC to better integrate into the innovation ecosystem.

Venture Day in Spring 2022

Duke partners with UNC and the NC Biotech Center to put on a university life science startup pitch day for invited investors.


This year, we helped
launch a variety of
start-ups – from next-gen animal collars to epigenetic therapeutic platforms.

RETHYMIC receives FDA approval

First ever therapy for congenital athymia, based on licensed Duke research, gets the FDA seal of approval.

December 12th, 2022
4th Annual Invented at Duke Celebration

Duke’s Office for Translation & Commercialization would like to invite you to the triumphant in-person return of Invented at Duke, the annual celebration and showcase of Duke inventors and inventions. It will be held 5-8PM at the Penn Pavilion on Duke campus.

The event will include remarks from President Price and featured speaker Dr. Joe Knight, former CEO of recently-acquired InnAVasc, inventors with booths, drinks and hors d’oeuvres, gifts for Duke inventors who register and attend, and more. We hope to see you there!



The first step in taking a research idea out of the lab.

Bridgestone invests in Duke start-up Tyrata

Tyrata’s automated tire depth measurement platform continues to drive the industry forward.

Kriya acquires Duke start-up Warden Bio

Gene therapy therapies developed by Duke researchers will continue to be developed for glycogen storage disorders.

New Drug Application for Elacestrant submitted to the FDA

Menarini Group and Radius Health continue to make great progress on a breast cancer therapeutic licensed from Duke.